Ioannis A Ziogas1, Muhammad A Rauf1, Lea K Matsuoka1, Manhal Izzy2, Scott A Rega3, Irene D Feurer4, Sophoclis P Alexopoulos1. 1. Department of Surgery, Division of Hepatobiliary Surgery and Liver Transplantation, Vanderbilt University Medical Center, Nashville, TN. 2. Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, TN. 3. Vanderbilt Transplant Center, Vanderbilt University Medical Center, Nashville, TN. 4. Department of Surgery, Department of Biostatistics, Vanderbilt Transplant Center, Vanderbilt University Medical Center, Nashville, TN.
Abstract
BACKGROUND: While liver transplantation (LT) with neoadjuvant chemoradiation is increasingly utilized for the management of unresectable cholangiocarcinoma (CCA), data on post-LT survival are limited. METHODS: We identified 844 patients who underwent LT (2002-2019) for nonincidental (CCA listing) or incidental (CCA on explant, not at listing) CCA in the Scientific Registry of Transplant Recipients. Kaplan-Meier and multivariable proportional hazards regression methods evaluated the effects of patient characteristics, donor type, transplant era (before/after 2010), and center volume (center-level CCALTs/active year) on the risk of graft failure and patient mortality. RESULTS: One center performed >12 CCALTs/y, and the rest performed ≤4. Five-year graft survival was 50.6%. Multivariable models demonstrated laboratory model of end-stage liver disease ≥40 versus <15 and center volumes of 1, >1 to ≤2, and >2 to ≤4 CCALTs/y compared to >12 were associated with increased risk of graft failure and mortality (all P ≤ 0.002). Extra vessel use was associated with center volume. Among all recipients, extra vessel use occurred in 55.4% of CCALTs performed at the highest volume center and in 14.0% of cases at centers having ≤4 CCAs/y (P < 0.05). CONCLUSIONS: Center volume-related differences in outcomes and extra vessel use highlight the importance of establishing a unified, effective treatment protocol and the potential utility of regionalization of LT for CCA.
BACKGROUND: While liver transplantation (LT) with neoadjuvant chemoradiation is increasingly utilized for the management of unresectable cholangiocarcinoma (CCA), data on post-LT survival are limited. METHODS: We identified 844 patients who underwent LT (2002-2019) for nonincidental (CCA listing) or incidental (CCA on explant, not at listing) CCA in the Scientific Registry of Transplant Recipients. Kaplan-Meier and multivariable proportional hazards regression methods evaluated the effects of patient characteristics, donor type, transplant era (before/after 2010), and center volume (center-level CCALTs/active year) on the risk of graft failure and patient mortality. RESULTS: One center performed >12 CCALTs/y, and the rest performed ≤4. Five-year graft survival was 50.6%. Multivariable models demonstrated laboratory model of end-stage liver disease ≥40 versus <15 and center volumes of 1, >1 to ≤2, and >2 to ≤4 CCALTs/y compared to >12 were associated with increased risk of graft failure and mortality (all P ≤ 0.002). Extra vessel use was associated with center volume. Among all recipients, extra vessel use occurred in 55.4% of CCALTs performed at the highest volume center and in 14.0% of cases at centers having ≤4 CCAs/y (P < 0.05). CONCLUSIONS: Center volume-related differences in outcomes and extra vessel use highlight the importance of establishing a unified, effective treatment protocol and the potential utility of regionalization of LT for CCA.
Authors: I De Vreede; J L Steers; P A Burch; C B Rosen; L L Gunderson; M G Haddock; L Burgart; G J Gores Journal: Liver Transpl Date: 2000-05 Impact factor: 5.799
Authors: Julie K Heimbach; Gregory J Gores; Michael G Haddock; Steven R Alberts; Rachel Pedersen; Walter Kremers; Scott L Nyberg; Michael B Ishitani; Charles B Rosen Journal: Transplantation Date: 2006-12-27 Impact factor: 4.939
Authors: Ek Khoon Tan; Charles B Rosen; Julie K Heimbach; Gregory J Gores; Daniel Zamora-Valdes; Timucin Taner Journal: J Am Coll Surg Date: 2020-02-06 Impact factor: 6.113
Authors: Sarwa Darwish Murad; W Ray Kim; Terry Therneau; Gregory J Gores; Charles B Rosen; James A Martenson; Steven R Alberts; Julie K Heimbach Journal: Hepatology Date: 2012-07-17 Impact factor: 17.425
Authors: Ioannis A Ziogas; Laura A Hickman; Lea K Matsuoka; Manhal Izzy; Martin I Montenovo; Scott A Rega; Irene D Feurer; Sophoclis P Alexopoulos Journal: Liver Transpl Date: 2020-07-21 Impact factor: 5.799
Authors: Debra Sudan; Arnaud DeRoover; Srinath Chinnakotla; Ira Fox; Byers Shaw; Tim McCashland; Mike Sorrell; Margaret Tempero; Alan Langnas Journal: Am J Transplant Date: 2002-09 Impact factor: 8.086
Authors: Julie K Heimbach; Gregory J Gores; Michael G Haddock; Steven R Alberts; Scott L Nyberg; Michael B Ishitani; Charles B Rosen Journal: Semin Liver Dis Date: 2004-05 Impact factor: 6.115